TGFBR1 and neoplasm: By blocking TGF-β1 signaling via pan-TGF-β neutralizing mAb 1D11 or TGF-β receptor inhibitors (galunisertib, targets both TGFβR1 and TGFβR2; SB431542, targets TGFβR1), tumor cell invasiveness and EMT can be abolished.